Chair, Chief Executive
Amgen Inc.
Bradway joined biotech giant Amgen in 2006, becoming chief executive in 2012 and chair a year later. The company has a market cap of nearly $160 billion, making it the second largest public company in the Los Angeles area. Amgen’s 2023 acquisition of Dublin-based Horizon Therapeutics for $27.8 billion began paying dividends last year, boosting revenues and solidifying a new business line for therapeutics for rare diseases. Revenue last year topped $33 billion. Amgen has also won federal approvals to increase the number of diseases and conditions that several of its existing drugs can treat, which has further boosted revenues. Prior to joining Amgen, Bradway spent 20 years at Morgan Stanley, rising through the ranks to become managing director.
YEARS ON LA500: 10
